Ram Selvaraju Maintains Buy Rating on Soleno Therapeutics

Summary

Ram Selvaraju has issued a Buy rating for Soleno Therapeutics, citing reduced competition following ACADIA Pharmaceuticals’ setback with intranasal carbetocin. The strong performance of VYKAT XR in the U.S. market, along with optimistic sales projections and ongoing European regulatory review, enhances its commercial prospects. Selvaraju, a 5-star analyst, supports his rating with a 20.3% average return. Stifel Nicolaus also maintains a Buy rating with a $118.00 price target.Tip Ranks

Impact Analysis

So basically, Ram Selvaraju’s Buy rating for Soleno Therapeutics hinges on a few key factors: reduced competition due to ACADIA Pharmaceuticals’ setback, and the strong performance of VYKAT XR in the U.S. market. The timing is interesting because it coincides with optimistic sales projections and ongoing European regulatory review, which could further boost commercial prospects. Selvaraju’s track record as a 5-star analyst with a 20.3% average return adds credibility to his rating. Stifel Nicolaus also backs this sentiment with a Buy rating and a $118.00 price target.Tip Ranks The market might be underestimating the impact of reduced competition and the potential regulatory approval in Europe. This could be a good entry point before broader market recognition.